PAIN: A Project Assessing the Impact of a Novel Cannabinoid Product
Active, not recruitingPhase 2NCT03984565
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
This study is a clinical trial of a high-cannabidiol (CBD) sublingual product compared to placebo for 9 weeks in patients with chronic pain conditions. The study will assess the impact of CBD on chronic pain symptoms, conventional medication use, clinical state, quality of life, cognition, and biomarkers.
Study details
- Official title
- PAIN: A Project Assessing the Impact of a Novel Cannabinoid Product
- Conditions
- Interventions
- Sponsor
- Staci Gruber, Ph.D.
- Collaborators
- Etheridge Foundation
- Organization
- Mclean Hospital
- Start date
- 2024-06-27
- Primary completion
- 2026-11
- Sex
- All
- Age range
- from 21 Years
- Results posted
- No results posted in this snapshot
- Countries
- United States
- Total sites listed
- 1
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: * Subject has provided informed consent * Subject is 21 or older * Subject is fluent in English * Subject endorses a musculoskeletal chronic pain condition including, but not limited to, chronic pain due to injury, arthritis (including osteoarthritis and rheumatoid arthritis), bursitis, etc. Exclusion Criteria: * Non-fluent English speakers * Estimated IQ \< 75 * A history of head injury or loss of consciousness greater than 5 minutes * Currently uses CBD products regularly * Female subjects will be excluded if they have a positive urine pregnancy test, are trying to become pregnant, or are currently breastfeeding * Presence of a serious or unstable medical illness, including liver, kidney, or cardiovascular disease (hyper/hypotension, cardiac disorders), or neurological disorder (including seizure disorder) * Primary neuropathic pain or cancer-related pain; patients experiencing neuropathic pain secondary to musculoskeletal pain will be allowed to enter the study * Disclosure of a genetic polymorphism affecting CYP2C9 function
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT03984565